ARA-290 10 MG

What is ARA-290?

ARA-290 (also known as cibinetide) is an investigational synthetic peptide derived from erythropoietin (EPO). Unlike EPO, ARA-290 does not stimulate red blood cell production. Instead, it is designed to selectively activate the innate repair receptor (IRR), a receptor involved in tissue protection and healing following injury or inflammation.

How does it work?

Research suggests ARA-290 may:

• Activate the innate repair receptor (IRR)
• Reduce inflammation
• Protect nerve cells from injury
• Promote tissue repair
• Reduce neuropathic pain
• Improve small nerve fiber function
• Decrease inflammatory signaling
• Support recovery following tissue damage

Unlike erythropoietin, ARA-290 has not been shown to increase red blood cell production at the doses studied.

What is ARA-290 studied for?

Research has explored ARA-290 for:

Small Fiber Neuropathy (SFN)

• Burning pain
• Tingling
• Numbness
• Autonomic nerve dysfunction

This is one of the most extensively studied applications.

Neuropathic pain

Including pain associated with:

• Diabetes
• Nerve injury
• Chronic pain syndromes

Sarcoidosis-associated neuropathy

Researchers have investigated whether ARA-290 may improve:

• Pain
• Fatigue
• Quality of life
• Small nerve fiber function

Diabetes

Studies have explored:

• Diabetic neuropathy
• Metabolic inflammation
• Nerve repair

Autoimmune disorders

Experimental research has evaluated its potential role in reducing inflammation and supporting tissue repair.

Kidney injury

Animal and early clinical studies have investigated protective effects against acute kidney injury.

Cardiovascular injury

Researchers have studied ARA-290 for its potential to reduce tissue damage following ischemia and reperfusion.

Wound healing

Because of its regenerative properties, ARA-290 has also been explored for tissue repair after injury.

Potential effects observed in studies

Early research has suggested ARA-290 may:

• Reduce neuropathic pain
• Improve nerve function
• Promote small nerve fiber regeneration
• Improve autonomic nervous system function
• Reduce inflammation
• Improve quality of life in some patients with chronic neuropathic conditions

While some studies have shown encouraging results, larger clinical trials are still needed to determine its effectiveness across different conditions.

What is ARA-290 commonly stacked with?

There are no established or evidence-based stacking protocols for ARA-290. Most discussion of combinations comes from experimental or research settings rather than standard medical practice.

BPC-157

Studied for:

• Soft tissue healing
• Gastrointestinal healing
• Recovery after injury

Research rationale:

• Both have been investigated for tissue repair, but through different biological pathways.

TB-500 (Thymosin Beta-4)

Studied for:

• Tissue regeneration
• Wound healing
• Muscle and tendon repair

Research rationale:

• Investigated as another regenerative peptide with mechanisms distinct from ARA-290.

GHK-Cu

Studied for:

• Skin repair
• Wound healing
• Collagen production

Research rationale:

• Explored for complementary effects on tissue remodeling and repair.

Cerebrolysin

Studied for:

• Neuroprotection
• Stroke recovery
• Traumatic brain injury
• Cognitive disorders

Research rationale:

• Both compounds have been investigated for protecting nervous tissue, though they target different biological mechanisms.

Lion's Mane (Hericium erinaceus)

Studied for:

• Nerve growth factor (NGF)
• Cognitive health
• Peripheral nerve regeneration

Research rationale:

• Investigated for potential support of nerve regeneration alongside other neuroregenerative strategies.

Alpha-lipoic acid (ALA)

Studied for:

• Diabetic neuropathy
• Oxidative stress
• Nerve function

Research rationale:

• ALA has established research in diabetic neuropathy and has been evaluated separately for improving neuropathic symptoms.

Acetyl-L-carnitine (ALCAR)

Studied for:

• Peripheral neuropathy
• Nerve regeneration
• Mitochondrial function

Research rationale:

• Investigated for supporting nerve health and cellular energy metabolism.

Current evidence

The strongest areas of research for ARA-290 include:

• Small fiber neuropathy
• Sarcoidosis-associated neuropathy
• Neuropathic pain
• Tissue protection and repair

Summary

ARA-290 (cibinetide) is an experimental peptide that activates the innate repair receptor, with the goal of promoting tissue repair while reducing inflammation and nerve damage. It has been studied primarily for small fiber neuropathy, neuropathic pain, sarcoidosis-associated neuropathy, diabetic nerve injury, kidney injury, and tissue repair. In research and experimental settings, it has sometimes been discussed alongside BPC-157, TB-500, GHK-Cu, Cerebrolysin, Lion's Mane, alpha-lipoic acid, and acetyl-L-carnitine, but no clinically established stacking protocols exist, and these combinations have not been validated in large human trials.